title: In vivo CD40-CD154 (CD40 ligand) interaction induces integrated HIV expression by APC in an HIV-1-transgenic mouse model.
abstract: Because of their relative resistance to viral cytopathic effects, APC can provide an alternative reservoir for latently integrated HIV. We used an HIV-transgenic mouse model in which APC serve as the major source of inducible HIV expression to study mechanisms by which integrated virus can be activated in these cells. When admixed with transgenic APC, activated T lymphocytes provided a major contact-dependent stimulus for viral protein expression in vitro. Using blocking anti-CD154 mAb as well as CD154-deficient T cells, the HIV response induced by activated T lymphocytes was demonstrated to require CD40-CD154 interaction. The role of this pathway in the induction of HIV expression from APC in vivo was further studied in an experimental model involving infection of the HIV-transgenic mice with PLASMODIUM: chabaudi parasites. Enhanced viral production by dendritic cells and macrophages in infected mice was associated with up-regulated CD40 expression. More importantly, in vivo treatment with blocking anti-CD154 mAb markedly reduced viral expression in P. chabaudi-infected animals. Together, these findings indicate that immune activation of integrated HIV can be driven by the costimulatory interaction of activated T cells with APC. Because chronic T cell activation driven by coinfections as well as HIV-1 itself is a characteristic of HIV disease, this pathway may be important in sustaining viral expression from APC reservoirs.
authors.affiliation: Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: C
authors.initials: C
authors.lastname: Chougnet
authors.forename: C
authors.initials: C
authors.lastname: Freitag
authors.forename: M
authors.initials: M
authors.lastname: Schito
authors.forename: E K
authors.initials: EK
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Sher
authors.forename: G M
authors.initials: GM
authors.lastname: Shearer
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000821:virology*; D000998:Antiviral Agents / Q000494:pharmacology; D019013:CD40 Antigens / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D023201:CD40 Ligand / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D002450:Cell Communication / Q000235:genetics / Q000276:immunology; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology; D005260:Female; D015497:HIV-1 / Q000235:genetics* / Q000254:growth & development / Q000276:immunology*; D008213:Lymphocyte Activation / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D018448:Models, Immunological; D016788:Plasmodium chabaudi / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000821:virology; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D014775:Virus Activation / Q000276:immunology; D016662:Virus Integration / Q000235:genetics / Q000276:immunology*
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D019013:CD40 Antigens; D023201:CD40 Ligand